Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeutART phase 1 study of CAP256V2LS and VRC07-523LS with ART in adults with HIV infection
PACTR202309578224660Phase 1Not yet recruiting
- Sponsor
- CAPRISA
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAP256V2LS and VRC07-523LS in human immunodeficiency virus infection (HIV), sponsored by CAPRISA. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
CAP256V2LSVRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202309578224660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202309578224660.